Evidence map›Paper›PMID 39449087›Full record

ArticlePneumonia (Nathan Qld.)2024

Effect of the Covid-19 pandemic on hospitalizations for non-Covid-19-pneumonia and exacerbations of chronic obstructive pulmonary diseases in Switzerland: comparison of national data between 2020/2021 and 2015-2019.

Carla Bürke, Florent Baty, Frank Rassouli, Martin H Brutsche, Werner C Albrich

Abstract read
In one paragraph

Article in Pneumonia (Nathan Qld.), 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Article
  2. Article
  3. Observational
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Carla BürkeDivision of Infectious Diseases, Infection Prevention and Travel Medicine, Cantonal Hospital St. Gallen, University Teaching and Research Hospital, Rorschacherstrasse 95, St. Gallen, CH-9007, Switzerland.
Florent BatyLung Center, Cantonal Hospital St. Gallen, St. Gallen, Switzerland.
Frank RassouliLung Center, Cantonal Hospital St. Gallen, St. Gallen, Switzerland.
Martin H BrutscheLung Center, Cantonal Hospital St. Gallen, St. Gallen, Switzerland.
Werner C AlbrichDivision of Infectious Diseases, Infection Prevention and Travel Medicine, Cantonal Hospital St. Gallen, University Teaching and Research Hospital, Rorschacherstrasse 95, St. Gallen, CH-9007, Switzerland. werner.albrich@kssg.ch.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundProtective measures applied during the Covid-19 pandemic had a marked impact on the incidence of pneumonia. However, systematic data are lacking for hospitalizations for pneumonia and acute exacerbations of chronic obstructive lung diseases (AECOPD) not caused by SARS-CoV-2 in Switzerland. We aimed to compare the incidences of hospitalization for these entities between 2020/2021 and prepandemic years.

methodsThis retrospective study examined all nationwide hospitalizations for non-Covid-19-pneumonia and AECOPD listed as primary diagnoses based on ICD-10 codes between 2015 and 2021 in a publicly available hospitalization database of the Swiss Federal Statistical Office. Hospitalizations for acute coronary syndrome (ACS) and stroke were used as controls. Changes of monthly incidences of hospitalizations, length of stay (LOS) and mortality were compared between 2020/2021 and the average of 2015-2019.

resultsThe incidences of hospitalizations for AECOPD and for pneumonia showed seasonal variations from 2015 to 2019 followed by significant and almost identical decreases in 2020/2021 (incidence rate ratio [IRR] 0.59, 95% CI: 0.45-0.77, p < 0.001, and IRR: 0.62, 95% CI: 0.52-0.74, p < 0.001, respectively). Hospital-mortality was slightly higher in 2020/2021 for AECOPD (2015-2019: 3.8%; 2020/2021: 4.2%, odds ratio [OR] 1.24, 95% CI: 1.07-1.44, p = 0.004) and for pneumonia (2015-2019: 4.5%, 2020/2021: 4.6%, odds ratio [OR] 1.17, 95% CI: 1.07-1.28, p < 0.001). Median LOS slightly decreased for AECOPD (2015-2019: 8 [IQR: 5-14] days; 2020/2021: 7 [IQR: 4-13] days, Wilcoxon test: p < 0.001) but slightly increased for pneumonia (2015-2019: 7 [IQR: 4-11] days; 2020/2021: 7 [IQR: 4-13] days, Wilcoxon test: p < 0.001). Throughout 2020/2021, there were no significant fluctuations observed in the incidences of ACS and stroke. (IRR: 0.98, 95% CI: 0.83-1.16, p = 0.810, IRR: 0.96, 95% CI: 0.81-1.14, p = 0.636, respectively).

conclusionThe first two years of the Covid-19 pandemic showed a marked decrease in incidences in AECOPD and non-Covid-19 pneumonia hospitalizations in Switzerland. It is likely that this effect is associated with the society-based, at first vigorous, social distancing measures.

Indexed as

Acute exacerbations of COPD (AECOPD)COPDCovid-19Covid-19 restrictionsPneumonia

Identifiers

PMID39449087
PMCPMC11520113

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.